New pill aims to boost red blood cells in MDS patients
NCT ID NCT05568225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a daily pill called etavopivat in 17 adults with very low, low, or intermediate risk MDS who had anemia. The goal was to see if the drug could improve red blood cell counts and reduce the need for transfusions. The study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etavopivat (a drug taken as a pill once daily to help increase red blood cell levels)
What this could lead to
If it works, this could offer a new oral treatment option for anemia in people with certain types of MDS, reducing the need for blood transfusions.
What could go wrong
This was a small, early-phase study that was terminated early, so results are limited. It is not yet clear if etavopivat is safe or effective for MDS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Plainsboro, New Jersey, 08536, United States
-
Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-1
Pessac, 33600, France
-
Charite Universitätsmedizin Berlin
Mainz, 55124, Germany
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Hopital Saint Louis
Paris, France
-
Master centre for France
Paris La Défense, 92936, France
-
NYU Langone Health
New York, New York, 10016, United States
-
Nice University Hospital - Hôpital de l'Archet
Route de Saint-Antoine, Nice, 06200, France
-
Northwell Health
Plainsboro, New Jersey, 08536, United States
-
Northwestern Memorial Hospital
Plainsboro, New Jersey, 08536, United States
-
Ocala Oncology
Ocala, Florida, 34474, United States
-
The Ohio State University Medical Center
Plainsboro, New Jersey, 08536, United States
-
Universitaetsklinikum Muenster
Münster, Germany
-
Universitoetsklinikum Halle (Saale)
Münster, Germany
-
Universitoetsklinikum Heidelberg
Heidelberg, Germany
-
University of British Columbia - St. Paul's Hospital
Vancouver, British Columbia, V6Z 2K5, Canada
-
University of Miami Hospital and Clinics
Miami, Florida, 33136, United States
-
Universitätsklinikum Leipzig, Klinik und Poliklinik
Mainz, 55124, Germany